3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Conditions
Multiple Myeloma
20
Recurrence
3
Neoplasms, Plasma Cell
3
Immunoglobulin Light-chain Amyloidosis
2
Amyloidosis
2
Plasmablastic Lymphoma
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recurrence
×
belantamab mafodotin
×
90 days
×
Clear all
NCT05714839
2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2
Recruiting
152 enrolled
NCT05064358
2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2
Completed
177 enrolled
37 charts
NCT02343042
2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2
Active not recruiting
300 enrolled